RECRUITINGOBSERVATIONAL
RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment
RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment: a Prospective, Multicentric, Cohort Study (RAISE)
About This Trial
The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as preventive migraine treatment in a cohort of episodic or chronic migraine patients.
Who May Be Eligible (Plain English)
Who May Qualify:
- Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III);
- At least 4 monthly migraine days;
- Good compliance to study procedures;
- Availability of headache diary at least of the preceding months before enrollment.
Who Should NOT Join This Trial:
- Subjects with contraindications for use of gepants;
- Concomitant diagnosis of medical diseases and/or comorbidities that, in the Investigator's opinion might interfere with study assessments;
- medical comorbidities that could interfere with study results;
- Pregnancy and breastfeeding.
- Changes in preventive treatments in the month before the first administration of rimegepant
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III);
* At least 4 monthly migraine days;
* Good compliance to study procedures;
* Availability of headache diary at least of the preceding months before enrollment.
Exclusion Criteria:
* Subjects with contraindications for use of gepants;
* Concomitant diagnosis of medical diseases and/or comorbidities that, in the Investigator's opinion might interfere with study assessments;
* medical comorbidities that could interfere with study results;
* Pregnancy and breastfeeding.
* Changes in preventive treatments in the month before the first administration of rimegepant
Treatments Being Tested
DRUG
Rimegepant 75 mg
Patients using Rimegepant 75 mg orally disintegrating tablet every other day as migraine prevention
Locations (2)
SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi
Florence, Italy
IRCCS National Neurological Institute "C. Mondino" Foundation
Pavia, Italy